Brief: Hansoh Pharmaceutical Says License Application Of Osteosarcoma Injection Accepted By NMPA
24/09/2026 12:33
BRIEF-Hansoh Pharmaceutical Says License Application Of Osteosarcoma Injection Accepted By NMPA Sept 24 (Reuters) - Hansoh Pharmaceutical Group Company Limited 3692.HK:
BIOLOGICS LICENSE APPLICATION OF RISVUTATUG REZETECAN FOR INJECTION (HS-20093) FOR OSTEOSARCOMA ACCEPTED BY NMPA
Further company coverage: 3692.HK
((reuters.briefs@thomsonreuters.com))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion